China, Emerging Markets In Focus For Genentech On Broad Avastin Access In Cervical Cancer
This article was originally published in PharmAsia News
Executive Summary
U.S. FDA approval is fifth indication for Roche/Genentech’s Avastin. The number of cases in the U.S. is low and set to decline with better prevention, but disease is still considered a major global health problem.